Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

histrelin acetate

(his-TREH-lin A-seh-tayt)
A drug used under the brand name Vantas as palliative therapy for advanced prostate cancer. Histrelin acetate initially causes the pituitary gland to make more luteinizing hormone (LH) and follicle-stimulating hormone (FSH), temporarily increasing testosterone levels in men. With continued use, histrelin acetate lowers the amount of LH and FSH the pituitary gland releases, leading to a drop in testosterone levels. Histrelin acetate is also used under the brand name Supprelin LA to treat early puberty in males and females. It is a type of hormone therapy called a luteinizing hormone-releasing hormone (LHRH) agonist and a type of androgen deprivation therapy that is reversible.
Search NCI's Dictionary of Cancer Terms